Vitadio is a pioneering company in prescription digital therapeutics focused on reversing insulin resistance with AI-driven lifestyle modification.

Our purpose is to empower people to restore their cardiometabolic health by creating digital therapies that treat the root cause of chronic conditions, not just the symptoms. We aim to improve health one habit at a time without side effects.

The first digital therapy for type 2 diabetes, Vitadio is covered by all statutory health insurers in Germany and currently available in Czech, Italian, and German languages. The company is headquartered in Prague and Berlin and expanding across Europe.

Vitadio combines evidence-based content and complex user data to deliver personalized therapy, AI-driven real-time diet feedback, and proactive human support through personal dietitians and social networks.

The platform is a Class I medical device under MDR, ISO 27001 and GDPR compliant, developed by healthcare professionals.

The clinical effect of Vitadio's digital therapeutics is comparable to modern antidiabetic drugs, with studies showing significant HbA1c reduction and weight loss outcomes.

Research partners include Technische Universität Dresden and University Olomouc, and major pharmaceutical players such as AstraZeneca and Novo Nordisk augment their pharmacotherapy with Vitadio.

Vitadio offers career opportunities for those passionate about healthcare innovation. Contact info includes [email protected] for partners and [email protected] for career inquiries. Their LinkedIn page is https://www.linkedin.com/company/vitadio/ and job posts are available at https://vitad.io/career.